We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
Read MoreHide Full Article
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report first-quarter 2025 results on April 23, after market close.
In the last reported quarter, the company’s adjusted earnings per share of 59 cents beat the Zacks Consensus Estimate by 7.27%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 2.60%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Q1 Estimates
The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues is pegged at $1.40 billion, suggesting a 12.2% decline from the year-ago reported figure.
The Zacks Consensus Estimate for first-quarter 2025 net earnings of 60 cents per share indicates a 9.1% decline from the year-ago reported figure.
Factors at Play
In September 2024, Edwards completed the $4.2 billion valued sell-off of its Critical Care product group to Becton, Dickinson and Company or BD, enabling it to sharpen its focus on structural heart disease. Despite being strategic, the absence of this segment is expected to have affected the company's first-quarter 2025 revenues on a year-over-year basis, given that the division generated $251.3 million in sales in the first quarter of 2024. On top of that, broader macroeconomic trends might have weighed upon the quarter’s results, including inflationary pressure, supply-chain constraints from geopolitical tensions and regulatory changes. Edwards’ business is likely continues to experience staffing shortages within the hospital systems, which may have also hindered its operational results.
In the first quarter of 2025, the Transcatheter Aortic Valve Replacement (TAVR) arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The ongoing launch of SAPIEN 3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes and the momentum is expected to have continued with more centers adopting it. We also expect steady sales in Japan in the first quarter, supported by the company’s efforts to address significant undertreatment of aortic stenosis among the country’s substantial elderly population.
During the February earnings call, Edwards stated that it experienced a few instances of regional pressure, despite holding a strong competitive position and stable global pricing. The trend is likely to have continued in the first quarter, restricting the segment’s full potential. Our model assumes TAVR sales to be $1.02 billion, reflecting a 1.6% year-over-year increase.
Edwards Lifesciences Corporation Price and EPS Surprise
In the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards’ performance in first-quarter 2025. The PASCAL repair system is expected to have gained traction both in the United States and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers. Additionally, the commercial launch of the EVOQUE tricuspid replacement system may have continued to progress in the U.S. and Europe.
Edwards has guided $500 million in sales from this segment in 2025, and we expect it to have progressed meaningfully in the first quarter. Our model estimates the TMTT business to report revenues of $1.20 billion, implying a 64.6% improvement from the year-ago period.
Lastly, Edwards’ Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. The company likely saw positive procedural growth globally for the many patients best treated surgically, including complex and concomitant procedures.
Our model estimates the segment’s first-quarter revenues to be $251.4 million, suggesting a modest 0.9% rise from the year-ago quarter’s reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
EW’s Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.41%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 61% from the year-ago quarter figure.
Veeva Systems (VEEV - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2026 results soon.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.92%. The Zacks Consensus Estimate for VEEV’s fiscal first-quarter EPS is expected to surge 16% from the year-ago reported figure.
Hims & Hers Health (HIMS - Free Report) has an Earnings ESP of +115.69% and a Zacks Rank #2. The company is slated to release first-quarter 2025 results on May 5.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 40.42%. The Zacks Consensus Estimate for Hims & Hers Health’s first-quarter EPS is expected to increase by 180% from the year-ago quarter figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report first-quarter 2025 results on April 23, after market close.
In the last reported quarter, the company’s adjusted earnings per share of 59 cents beat the Zacks Consensus Estimate by 7.27%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 2.60%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Q1 Estimates
The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues is pegged at $1.40 billion, suggesting a 12.2% decline from the year-ago reported figure.
The Zacks Consensus Estimate for first-quarter 2025 net earnings of 60 cents per share indicates a 9.1% decline from the year-ago reported figure.
Factors at Play
In September 2024, Edwards completed the $4.2 billion valued sell-off of its Critical Care product group to Becton, Dickinson and Company or BD, enabling it to sharpen its focus on structural heart disease. Despite being strategic, the absence of this segment is expected to have affected the company's first-quarter 2025 revenues on a year-over-year basis, given that the division generated $251.3 million in sales in the first quarter of 2024. On top of that, broader macroeconomic trends might have weighed upon the quarter’s results, including inflationary pressure, supply-chain constraints from geopolitical tensions and regulatory changes. Edwards’ business is likely continues to experience staffing shortages within the hospital systems, which may have also hindered its operational results.
In the first quarter of 2025, the Transcatheter Aortic Valve Replacement (TAVR) arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The ongoing launch of SAPIEN 3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes and the momentum is expected to have continued with more centers adopting it. We also expect steady sales in Japan in the first quarter, supported by the company’s efforts to address significant undertreatment of aortic stenosis among the country’s substantial elderly population.
During the February earnings call, Edwards stated that it experienced a few instances of regional pressure, despite holding a strong competitive position and stable global pricing. The trend is likely to have continued in the first quarter, restricting the segment’s full potential. Our model assumes TAVR sales to be $1.02 billion, reflecting a 1.6% year-over-year increase.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
In the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards’ performance in first-quarter 2025. The PASCAL repair system is expected to have gained traction both in the United States and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers. Additionally, the commercial launch of the EVOQUE tricuspid replacement system may have continued to progress in the U.S. and Europe.
Edwards has guided $500 million in sales from this segment in 2025, and we expect it to have progressed meaningfully in the first quarter. Our model estimates the TMTT business to report revenues of $1.20 billion, implying a 64.6% improvement from the year-ago period.
Lastly, Edwards’ Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. The company likely saw positive procedural growth globally for the many patients best treated surgically, including complex and concomitant procedures.
Our model estimates the segment’s first-quarter revenues to be $251.4 million, suggesting a modest 0.9% rise from the year-ago quarter’s reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
EW’s Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
EW’s Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Masimo (MASI - Free Report) has an Earnings ESP of +0.64% and a Zacks Rank #1. The company is expected to release first-quarter 2025 results soon. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.41%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 61% from the year-ago quarter figure.
Veeva Systems (VEEV - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2026 results soon.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.92%. The Zacks Consensus Estimate for VEEV’s fiscal first-quarter EPS is expected to surge 16% from the year-ago reported figure.
Hims & Hers Health (HIMS - Free Report) has an Earnings ESP of +115.69% and a Zacks Rank #2. The company is slated to release first-quarter 2025 results on May 5.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 40.42%. The Zacks Consensus Estimate for Hims & Hers Health’s first-quarter EPS is expected to increase by 180% from the year-ago quarter figure.